Market expecting 52 to 54m NPAT per the bell potter reporting calendar. It may not be a tech company but one could not be mistaken to think it is one if looking at the income statement alone - gross margin of near 80% with top line growth of around 60%. EBITDA ratio of 30% is very impressive as well - it is on par with high end healthcare companies that provide scarce resources.
PE is 40 for FY22 but for FY23, the PE is 30 or lower. Looking at the guidance provided I expect NPAT to increase 30%+ for FY23. This is in line with the CEOs long term incentives.
Ann: FY22 Full Year Results Presentation, page-7
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LOV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$31.37 |
Change
-0.400(1.26%) |
Mkt cap ! $3.441B | |||
| Open | High | Low | Value | Volume |
| $31.80 | $32.09 | $31.34 | $15.12M | 478.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2030 | $31.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $31.57 | 1 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| LOV (ASX) Chart |